http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김경곤,강지현,김은미 대한비만학회 2022 Journal of obesity & metabolic syndrome Vol.31 No.3
Background: Despite the considerable number of trials and meta-analyses of studies on intermittent energy restriction (IER), it is not preferred to continuous energy restriction (CER) by the majority of obesity specialists. In this meta-analysis, we compare the effects of IER and CER on obesity using evidence from randomized controlled trials (RCTs). Methods: A systematic electronic literature search was conducted to find RCTs published between January 1, 2011, and December 31, 2021 that directly compared IER and CER for an active weight loss period of at least 12 weeks and reported obesity indices or metabolic markers in adults with overweight or obesity. Finally, 16 RCTs from 25 articles with 1,438 participants were included. Results: The attrition rates were 26.6% and 24.1% in the IER and CER groups, respectively, with no significant differences in changes in body weight, waist circumference, or body fat composition. CER changed blood glucose levels more than IER, but there was no significant difference in glycated hemoglobin levels. Systolic blood pressure was significantly lower in the CER group than the IER group, but diastolic blood pressure did not differ significantly between the groups. Changes in blood lipids did not differ significantly between the interventions. No differences between IER and CER were observed in the sensitivity analyses. Conclusion: IER can be an alternative to CER because it induces comparable weight reduction and metabolic improvement. However, the effect of IER was not superior to that of CER, and its attrition rate was not lower than that of CER.
김경곤 대한비만학회 2015 The Korean journal of obesity Vol.24 No.1
Because of the widespread use of ant-obesity medications, bariatricians need to be aware not only of common adverse events but also uncommonserious events in the pharmacotherapy of obesity. Safety and tolerability must be considered in selecting the drug, titrating the dosage, andmonitoring patients. In Korea, orlistat and lorcaserine are the two anti-obesity drugs that can be used for long-term treatment, and in the US,liraglutide, phentermine/topiramate, and naltrexone/bupropion have been recently approved. In general, all of these drugs have very good safetyand tolerability profiles. Common adverse events of these drugs are well understood, and they can be coped with or prevented by adjusting thedosage properly. In addition, patients can recover from serious events by stopping the medication. However, there are other serious side effectsthat need to be monitored for. These include liver injury, acute kidney injury, and pancreatitis for orlistat; valvulopathy for lorcaserine; thyroidC-cell pathology and pancreatitis for liraglutide; metabolic acidosis, urolithiasis, acute angle closure glaucoma, and teratogenic effects for phentermine/topiramate; and severe nausea and heart disease for naltrexone/bupropion. 비만 치료제는 상당히 많은 사람들에게 장기간 투여되기 때문에,흔한 부작용 뿐만 아니라 드물게 일어나지만 심각한 부작용도 간과해서는 안된다. 약물을 선택하고 용량을 조절하고 추적 관찰하는 데 있어서 안전성 측면을 우선적으로 고려해야 한다. 우리나라에서 장기간사용이 가능한 비만 치료제에는 orlistat과 lorcaserine이 있으며, 미국의 경우에는 liraglutide, phentermine/topiramate, naltrexone/bupropion이비만 치료의 목적으로 장기간 사용에 대해 허가를 획득하였다. 이들 약제는 전반적으로 모두 내약성과 안전성이 뛰어난 약제이다. 이들에 대한 흔한 부작용들은 잘 알려져 있으며, 적절한 용량 조절을 통해서 예방하거나 대처할 수 있으며, 경우에 따라 약물 투여를 중지함으로써 부작용에서 회복될 수도 있다. 하지만 orlistat은 간 손상, 급성신증, 췌장염, lorcaserine은 심장판막증, liraglutide는 갑상선 C세포 이상, 췌장염, phentermine/topiramate는 대사성 산증, 신장 결석, 급성폐쇄성 녹내장, 태아 기형, 그리고 naltrexone/bupropion은 심한 구역감과 심장 질환이, 사용 시 주의를 기울여야 하는 심대한 부작용이다.